CJC-1295 without DAC + Ipamorelin Blend

CJC-1295 without DAC + Ipamorelin – Synergistic GH Research Peptide Blend

The CJC-1295 without DAC + Ipamorelin Blend is a dual-peptide research formulation combining a Growth Hormone–Releasing Hormone (GHRH) analogue and a Growth Hormone–Releasing Peptide (GHRP) to create a synergistic model for the study of growth hormone (GH) regulation. This combination enables the investigation of both GHRH receptor–mediated and ghrelin receptor (GHSR)–mediated GH release mechanisms in in-vitro experimental settings.

This reagent is produced under stringent laboratory protocols and tested using High-Performance Liquid Chromatography (HPLC) to confirm a purity of ≥99%. It is supplied as a lyophilized powder for use in controlled in-vitro endocrinological and biochemical research.

Blend Composition

• CJC-1295 without DAC – 5 mg: GHRH analogue examined in studies of pulsatile GH release via GHRH receptor activation.
• Ipamorelin – 5 mg: GHRP studied for selective activation of ghrelin receptors (GHSR) with minimal observed impact on cortisol and prolactin pathways in in-vitro models.

Key Specifications

• Name: CJC-1295 without DAC + Ipamorelin Blend
• Total Content: 10 mg (5 mg CJC-1295 without DAC + 5 mg Ipamorelin)
• Type: Combination of GHRH and GHRP analogues
• Form: Lyophilized Powder
• Purity: ≥99% (HPLC tested)
• Storage: Store refrigerated, protected from light and moisture
• Shelf life: Sealed lyophilizate. Shelf life 24 months from manufacture.

Research Applications

• Referenced in research on growth hormone secretion via dual receptor pathways.
• Enables investigation of GHRH and GHSR signaling synergy in in-vitro assay models.
• Used as a reagent in studies focused on metabolic regulation and GH stimulation protocols.
• Supplied in lyophilized form for long-term storage stability and assay reproducibility.

A batch-specific Certificate of Analysis (CoA) is available on request and accompanies every order.